Ceftolozane-tazobactam activity against phylogenetically diverse clostridium difficile strains

Mark D. Gonzalez, Meghan A. Wallace, Tiffany Hink, Erik R. Dubberke, Carey Ann D. Burnham

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Ceftolozane-tazobactam (C/T) is approved for the treatment of complicated intra-abdominal and urinary tract infections and has varied activity against anaerobic bacteria. Here, we evaluate the activity of C/T against a phylogenetically diverse collection of Clostridium difficile isolates and report uniformly high MICs (≥256 μg/ml) to C/T.

Original languageEnglish
Pages (from-to)7084-7085
Number of pages2
JournalAntimicrobial agents and chemotherapy
Volume59
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint Dive into the research topics of 'Ceftolozane-tazobactam activity against phylogenetically diverse clostridium difficile strains'. Together they form a unique fingerprint.

Cite this